Literature DB >> 9875645

Immediate onset of DNA synthesis in remnant rat liver after 90% hepatectomy by an administration of follistatin.

K Kogure1, Y Q Zhang, H Shibata, I Kojima.   

Abstract

BACKGROUND/AIM: Follistatin is an antagonist of activins and is effective in promoting liver regeneration after 70% hepatectomy. To examine its efficacy under more critical conditions, we studied the effect of follistatin on liver regeneration in 90% hepatectomized rat.
METHODS: Human recombinant follistatin was infused into the portal vein immediately after 90%, hepatectomy in 24-h-starved rats, and changes in the liver regeneration rate and nuclear bromodeoxyuridine labeling were measured.
RESULTS: In control rats, nuclear labeling was first detected at 11 h of hepatectomy. In follistatin-treated rats, nuclear labeling was markedly increased at 3 h, and was significantly higher than that in control rats at 24, 72, 96, 120 and 144 h. The liver regeneration rate was significantly higher in follistatin-treated rats at 48, 72, 96, 120, 144 and 168 h. To determine the reason for the accelerated growth in starved rats, we compared the expression of mRNA for c-myc, p53, p21CIP1, p15INK4B, p27KIP1, and subunits of activins in fed and starved rats. mRNA for p21CIP1 and p15INK4B, but not p27KIP1 were decreased in 24 h-starved rats compared to the fed rats. mRNA for betaA subunit of activin was not detected in either fed or 24-h-starved rats, whereas that for betaC subunit was increased in starved rats.
CONCLUSION: These results indicate that follistatin induces immediate onset of DNA synthesis in 90% hepatectomized rats and is quite effective in promoting liver regeneration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875645     DOI: 10.1016/s0168-8278(98)80126-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Marginal hepatectomy in the rat: from anatomy to surgery.

Authors:  Nodir Madrahimov; Olaf Dirsch; Christoph Broelsch; Uta Dahmen
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Expression changes of activin A in the development of hepatic fibrosis.

Authors:  X Huang; D G Li; Z R Wang; H S Wei; J L Cheng; Y T Zhan; X Zhou; Q F Xu; X Li; H M Lu
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.

Authors:  L Xu; A Y Hui; E Albanis; M J Arthur; S M O'Byrne; W S Blaner; P Mukherjee; S L Friedman; F J Eng
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

4.  Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression.

Authors:  N A Shackel; P H McGuinness; C A Abbott; M D Gorrell; G W McCaughan
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

5.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

Review 6.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

7.  Beneficial effects of follistatin in hepatic ischemia-reperfusion injuries in rats.

Authors:  Mami Kanamoto; Mitsuo Shimada; Yuji Morine; Tomoharu Yoshizumi; Satoru Imura; Toru Ikegami; Hiroki Mori; Yusuke Arakawa
Journal:  Dig Dis Sci       Date:  2010-09-08       Impact factor: 3.199

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Female infertility and disrupted angiogenesis are actions of specific follistatin isoforms.

Authors:  Shyr-Yeu Lin; Rebecca G Craythorn; Anne E O'Connor; Martin M Matzuk; Jane E Girling; John R Morrison; David M de Kretser
Journal:  Mol Endocrinol       Date:  2007-10-11

10.  Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?

Authors:  K Frost; K Seir; A Lackner; M Grusch; B Grasl-Kraupp; R Schulte-Hermann; C Rodgarkia-Dara
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.